Surgery has been limited to solving obstruction and small bowel perforation. Eosinophilic gastrointestinal disorders (EGID) constitute a pathology characterized by eosinophilic infiltration of the ...

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

Background and Aim Allergies have been implicated in the pathogenesis of eosinophilic gastrointestinal disorders, although it remains unknown what type of allergen is closely associated with their ...

Rothenberg, Director of the Cincinnati Center for Eosinophilic Disorders and Professor of Pediatrics at Cincinnati Children's Hospital Medical Center, USA. At present, there are no approved drugs ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis. IRL201104, is ...

eosinophilic esophagitis. DBV has also stated its intention to expand beyond food allergy therapies into vaccines and ...

The Fellow will have the opportunity to rotate through several multi-disciplinary clinics, including Eosinophilic disorders, Feeding Therapy, Inflammatory Bowel Disease, Colorectal Clinic, Intestinal ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...